-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In order to ensure the smooth implementation of national medicines and better meet the needs of insured patients for rational drug use, Zhejiang Province recently released a "dual-channel" catalog.
A total of 221 drugs under negotiation for national medical insurance are included in Zhejiang’s "dual-channel" management, including 162 western medicines.
And 59 kinds of Chinese patent medicines
.
Judging from the list, it includes the four major domestic monoclonal antibodies of Sintilizumab, Tilelizumab, Teriplizumab, and Karelizumab
.
Judging from the results of past medical insurance negotiations, the four major domestic PD-1 Hengrui Pharmaceuticals Carrelizumab, Cinda Biosintilizumab, BeiGene Tilelizumab, Junshi Bio-Trepril Monoclonal antibodies were successfully included in the medical insurance catalog with price drops of 85.
21%, 63.
73%, 79.
60%, and 70.
82%, with an overall decrease of 60%-85%
.
According to the analysis of Essence Securities, it is expected that in the national medical insurance negotiations in 2021, the overall reduction of PD-1 will be controllable (about 10% to 20%), and the annual fee will remain at the level of 35,000 to 40,000 after the price reduction
.
In addition, 6 GLP-1 categories that have been included in the medical insurance are also on the list, including exenatide, liraglutide, risnatide, benaglutide, dulaglutide, and polyethylene glycol.
Senatide
.
The 53 proprietary Chinese medicines include Xuebijing Injection, Ginkgolide Injection, Niuhuang Qinggan Capsules, Shuqing Granules, Qingweizhitong Pellets, Xiaoer Niuhuang Qingxin San and other varieties
.
"Dual channel" refers to the two channels of designated medical institutions and designated retail pharmacies to buy medicines.
The purpose is to meet the reasonable needs of negotiating drug supply guarantees and clinical use, and to simultaneously incorporate them into the medical insurance payment mechanism
.
In May 2021, the two ministries and commissions jointly issued the "Guiding Opinions on Establishing and Improving the "Dual Channel" Management Mechanism for National Medical Insurance Negotiation Drugs", clarifying that designated retail pharmacies should be included in the scope of medical insurance drug supply guarantee at the national level, and the implementation of uniformity with medical institutions Payment policy
.
According to the regulations of the National Medical Insurance Bureau, all provinces shall determine the list of medicines to be included in the "dual channel" management by the end of October and announce it to the public
.
Up to now, in addition to Zhejiang, provinces and cities including Guangdong, Anhui, Hunan, Jiangxi, Shanghai and other provinces and cities have successively begun to formulate implementation opinions of the "dual channel" management mechanism, and announced the "dual channel" management drug list
.
The industry predicts that as the "dual channel" policy is successively implemented in various places, it will help promote the reform of the drug management system in medical institutions, improve the service quality of medical insurance designated retail pharmacies, and solve the "difficulty in entering the hospital" and "difficulty in landing" negotiated drugs, so that medical insurance The negotiated drugs further achieved rapid increase in volume to better meet the people's drug demand
.
At the same time, the market structure inside and outside the hospital may change
.
The Ministry of Commerce proposed in October this year that by 2025, the industry will cultivate 1 to 3 large-scale digital and comprehensive drug distribution enterprises with a value of over 500 billion yuan, 5-10 billion yuan, and 5-10 over 500 billion yuan.
A professional and diversified pharmaceutical retail chain enterprise worth RMB 100 million
.
With the help of policies, it is expected that head pharmacies are expected to benefit, and the industry concentration will further increase
.
In its research report, Guojin Securities also pointed out: For pharmacies, the liberalization of the "dual channel" allows pharmacies to also undertake negotiations for drug delivery, increase passenger flow through prescription circulation, promote drug outflow, and optimize resource allocation; Compared with designated retail pharmacies, they have higher requirements for designated retail pharmacies that meet the requirements of "dual channel" management.
The research report summarizes them as information development, drug management in place, and medical insurance fund management standards
.
A total of 221 drugs under negotiation for national medical insurance are included in Zhejiang’s "dual-channel" management, including 162 western medicines.
And 59 kinds of Chinese patent medicines
.
Judging from the list, it includes the four major domestic monoclonal antibodies of Sintilizumab, Tilelizumab, Teriplizumab, and Karelizumab
.
Judging from the results of past medical insurance negotiations, the four major domestic PD-1 Hengrui Pharmaceuticals Carrelizumab, Cinda Biosintilizumab, BeiGene Tilelizumab, Junshi Bio-Trepril Monoclonal antibodies were successfully included in the medical insurance catalog with price drops of 85.
21%, 63.
73%, 79.
60%, and 70.
82%, with an overall decrease of 60%-85%
.
According to the analysis of Essence Securities, it is expected that in the national medical insurance negotiations in 2021, the overall reduction of PD-1 will be controllable (about 10% to 20%), and the annual fee will remain at the level of 35,000 to 40,000 after the price reduction
.
In addition, 6 GLP-1 categories that have been included in the medical insurance are also on the list, including exenatide, liraglutide, risnatide, benaglutide, dulaglutide, and polyethylene glycol.
Senatide
.
The 53 proprietary Chinese medicines include Xuebijing Injection, Ginkgolide Injection, Niuhuang Qinggan Capsules, Shuqing Granules, Qingweizhitong Pellets, Xiaoer Niuhuang Qingxin San and other varieties
.
"Dual channel" refers to the two channels of designated medical institutions and designated retail pharmacies to buy medicines.
The purpose is to meet the reasonable needs of negotiating drug supply guarantees and clinical use, and to simultaneously incorporate them into the medical insurance payment mechanism
.
In May 2021, the two ministries and commissions jointly issued the "Guiding Opinions on Establishing and Improving the "Dual Channel" Management Mechanism for National Medical Insurance Negotiation Drugs", clarifying that designated retail pharmacies should be included in the scope of medical insurance drug supply guarantee at the national level, and the implementation of uniformity with medical institutions Payment policy
.
According to the regulations of the National Medical Insurance Bureau, all provinces shall determine the list of medicines to be included in the "dual channel" management by the end of October and announce it to the public
.
Up to now, in addition to Zhejiang, provinces and cities including Guangdong, Anhui, Hunan, Jiangxi, Shanghai and other provinces and cities have successively begun to formulate implementation opinions of the "dual channel" management mechanism, and announced the "dual channel" management drug list
.
The industry predicts that as the "dual channel" policy is successively implemented in various places, it will help promote the reform of the drug management system in medical institutions, improve the service quality of medical insurance designated retail pharmacies, and solve the "difficulty in entering the hospital" and "difficulty in landing" negotiated drugs, so that medical insurance The negotiated drugs further achieved rapid increase in volume to better meet the people's drug demand
.
At the same time, the market structure inside and outside the hospital may change
.
The Ministry of Commerce proposed in October this year that by 2025, the industry will cultivate 1 to 3 large-scale digital and comprehensive drug distribution enterprises with a value of over 500 billion yuan, 5-10 billion yuan, and 5-10 over 500 billion yuan.
A professional and diversified pharmaceutical retail chain enterprise worth RMB 100 million
.
With the help of policies, it is expected that head pharmacies are expected to benefit, and the industry concentration will further increase
.
In its research report, Guojin Securities also pointed out: For pharmacies, the liberalization of the "dual channel" allows pharmacies to also undertake negotiations for drug delivery, increase passenger flow through prescription circulation, promote drug outflow, and optimize resource allocation; Compared with designated retail pharmacies, they have higher requirements for designated retail pharmacies that meet the requirements of "dual channel" management.
The research report summarizes them as information development, drug management in place, and medical insurance fund management standards
.
